このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

切除不能な肝がん患者の治療における高線量外照射療法後の改変免疫細胞(自家樹状細胞)とワクチン(Prevnar)

2026年9月30日 更新者:Mayo Clinic

切除不能な肝癌患者における高線量原体外照射放射線療法後の樹状細胞の腫瘍内注射に関するパイロット研究

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unresectable) after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab and durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving autologous dendritic cells and Prevnar in combination with immune checkpoint inhibition after radiotherapy may be safe, and tolerable and may stimulate the body's own immune system to fight against the tumor in patients with unresectable liver cancer.

調査の概要

詳細な説明

PRIMARY OBJECTIVE:

I. Evaluation of safety and tolerability of an autologous dendritic cell (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). (Pilot Study) II. Estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data in hepatocellular carcinoma (HCC). (Phase II Group 2) II. Estimate the progression-free survival to see if treatment is efficacious compared to historical data in intrahepatic cholangiocarcinoma (iCCA) patients. (Phase II Group 3)

SECONDARY OBJECTIVES:

I. To assess feasibility in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 versus [vs.] 2 vs. 3).

II. To assess overall response rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

III. To assess progression free survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

IV. To assess clinical benefit rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

V. To assess time to response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

VI. To assess duration of response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

VII. To assess overall survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

RADIOLOGIC STUDY OBJECTIVE:

I. To assess the radiologic response over time of primary liver tumors treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

CORRELATIVE RESEARCH OBJECTIVES:

I. To monitor patients' immune response after vaccine therapy by group (Group 1 vs. 2 vs. 3).

II. To assess the immune response to pneumococcal 13-valent conjugate vaccine (Prevnar) and similar pneumococcal vaccines by group (Group 1 vs. 2 vs. 3).

OUTLINE:

PILOT STUDY (GROUP I) (CLOSED WITH AMENDMENT 3): Patients with unresectable intrahepatic cholangiocarcinoma (CCA) undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells intratumorally (IT) on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine intramuscularly (IM) on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.

PHASE II STUDY (GROUP II): Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab intravenously (IV) over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an esophagogastroduodenoscopy (EGD) at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

PHASE II STUDY (GROUP III): Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 2 weeks and then every 3 months for 1 year (beginning at week 36 or 12 weeks after last autologous dendritic cell dose whichever is earlier). Patients are then followed every 3 months until disease progression, and then every 6 months until 5 years after registration.

研究の種類

介入

入学 (推定)

85

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic in Rochester
        • コンタクト:
        • 主任研究者:
          • Lewis R. Roberts, MD, PhD
        • 主任研究者:
          • Lionel Kankeu Fonkoua, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age >= 18 years

  • Pilot study (group 1): Histologic confirmation of intrahepatic CCA (Closed as of amendment 3)

  • Phase II study (group 2): Histologic and/or radiologic confirmation of hepatocellular carcinoma (HCC)

  • Phase II study (group 3): Histologic confirmation of intrahepatic cholangiocarcinoma (iCCA)

  • The following tumor characteristics must be met

    • Unresectable disease: HCC (group 2) or intrahepatic CCA (group 3)

    • Measurable or evaluable disease

    • All lesions should be treatable by EBRT while meeting normal tissue constraints

    • Tumor lesions should be accessible using an ultrasound (US)-guided approach for intratumoral DC injection

    • No evidence of extrahepatic tumor (excluding tumor thrombus) by computed tomography (CT) or magnetic resonance imaging (MRI) scan

      • NOTE: Patients who are not candidates for surgical treatment or for ablation with curative intent are allowed
  • Good candidate for standard of care high-dose conformal EBRT in the view of the investigator

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

  • GROUP 2 HCC ONLY: Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absolute lymphocyte count (ALC) >= 500/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absolute monocyte count (AMC) >= 300/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Platelet count >= 50,000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Hemoglobin >= 9.0 g/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Total bilirubin < 1.5 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Creatinine =< 2 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absence of proteinuria at screening as demonstrated by one of the following:

    • Urine protein/creatinine (UPC) ratio < 1.0 at screening OR
    • Urine dipstick for proteinuria < 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =<1g of protein in 24 hours to be eligible)
  • GROUP 3 iCCA ONLY: Absolute neutrophil count (ANC) ≥ 1000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Absolute lymphocyte count ≥ 500/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Absolute monocyte count ≥ 300/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Platelet count ≥ 50,000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Hemoglobin ≥ 9.0 g/dL (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Total bilirubin < 1.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Creatinine ≤ 2 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: PT/INR/aPTT ≤ 1.5 x ULN (obtained =< 15 days prior to registration)

    • NOTE: If patient is receiving therapeutic anticoagulation, patient must be on a stable anticoagulant regimen
  • Ability to provide written consent

  • Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)

  • Willingness to provide blood and tissue samples for correlative research purposes

Exclusion Criteria:

  • Any of the following because this study involves an investigational agent, the genotoxic, mutagenic and teratogenic effects of which on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ highly effective contraception during heterosexual intercourse while on this study and for 5 months after the last dose of study medication
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Immunocompromised patients and patients known to be HIV positive.

    • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial if they are stable on anti-retroviral therapy, have a CD4+ T cell count ≥ 200/uL, and have an undetectable viral load
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection requiring systemic treatment or that could impact patient safety
    • Severe infection ≤ 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
    • Significant cardiovascular disease (New York Heart Association [NYHA] class II), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
    • Or, psychiatric illness/social situations (e.g., substance abuse) that would limit compliance with study requirements
  • Receiving any other investigational agent that would be considered a treatment for the primary neoplasm

  • Other active malignancy =< 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes

  • Major surgery =< 4 weeks prior to enrollment (other than diagnostic surgery or surgical spacer placement in preparation for radiation treatment), or anticipation of need for a major surgical procedure during the study

  • History of hypersensitivity or anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid

  • Active or history of autoimmune disease or immune deficiency, including but not limited to,myasthenia gravis, myositis, autoimmune hepatitis, Crohn's disease, inflammatory bowel disease, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjogren syndrome, systemic lupus erythematosus, Guillain-Barre syndrome, multiple sclerosis, Wegener granulomatosis, or similar conditions

    • NOTE: Exceptions are allowed for:

      • Patients with hypothyroidism on thyroid replacement therapy

      • Patients with type 1 diabetes mellitus on insulin regimen

      • Patients with eczema, psoriasis lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of the following conditions are met:

        • Rash must cover < 10% of body surface area
        • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
        • There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids ≤ 12 months prior to registration
  • Requires anticoagulant treatment (INR > 1.5 x ULN) or use of anti-platelet agents that cannot be discontinued for the intratumoral injection procedure

    • NOTE: Heparin for line patency without detectable lab abnormalities in coagulation will be allowed
  • Corticosteroids =< 2 weeks prior to registration, including oral, intravenous (IV), subcutaneous, or inhaled routes of administration

    • NOTE: Patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)

    • NOTE: Exception allowed for patients who need prophylactic steroids prior to imaging for contrast allergies

      • Exception: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study
      • Exception: Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
  • History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

  • Child Pugh class B or C cirrhosis of the liver

  • Previously received immune modulating therapies including but not limited to immune checkpoint inhibitors targeting PD-1 PDL-1 CTLA4, etc.; or prior dendritic cell therapy

  • Prior liver radiation, including radioembolization

  • GROUP 2 ONLY: Barcelona Clinic Liver Cancer (BCLC) stage D disease

  • GROUP 2 ONLY: History of untreated high-risk gastroesophageal varices

  • Active tuberculosis

  • Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to registration

    • NOTE: Exception for patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
  • Prior allogeneic stem cell or solid organ transplantation

  • Treatment with a live, attenuated vaccine ≤ 4 weeks prior to registration

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phase II Group 2 (EBRT, dendritic cells, Prevnar, atezo, bev)

Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an EGD at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

Given IV

他の名前:
  • アバスチン
  • ABP 215
  • 抗VEGF
  • 抗VEGFヒト化モノクローナル抗体
  • 抗VEGFモノクローナル抗体SIBP04
  • 抗VEGF rhuMAb
  • ベバシズマブ
  • ベバシズマブ バイオシミラー ABP 215
  • ベバシズマブ バイオシミラー BEVZ92
  • ベバシズマブ バイオシミラー BI 695502
  • ベバシズマブ バイオシミラー CBT 124
  • ベバシズマブ バイオシミラー CT-P16
  • ベバシズマブ バイオシミラー FKB238
  • ベバシズマブ バイオシミラー GB-222
  • ベバシズマブ バイオシミラー HD204
  • ベバシズマブ バイオシミラー HLX04
  • ベバシズマブ バイオシミラー IBI305
  • ベバシズマブ バイオシミラー LY01008
  • ベバシズマブ バイオシミラー MIL60
  • ベバシズマブ バイオシミラー Mvasi
  • ベバシズマブ バイオシミラー MYL-1402O
  • ベバシズマブ バイオシミラー QL 1101
  • ベバシズマブ バイオシミラー RPH-001
  • ベバシズマブ バイオシミラー SCT501
  • ベバシズマブ バイオシミラー ジラベフ
  • ベバシズマブ-awwb
  • ベバシズマブ-bvzr
  • BP102
  • BP102 バイオシミラー
  • HD204
  • 免疫グロブリン G1 (ヒト-マウス モノクローナル rhuMab-VEGF ガンマ鎖抗ヒト血管内皮成長因子)、ヒト-マウス モノクローナル rhuMab-VEGF 軽鎖を含むジスルフィド、二量体
  • ムヴァシ
  • MYL-1402O
  • 組換えヒト化抗VEGFモノクローナル抗体
  • rhuMab-VEGF
  • SCT501
  • SIBP04
  • SIBP-04
  • ジラベフ
  • QL1101
  • ベバシズマブ バイオシミラー QL1101
  • ベグゼルマ
  • アリムシス
  • アイビンティオ
  • オンベブジ
  • アヴジヴィ
  • オヤバス

Undergo MRI

他の名前:
  • MRI
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 構造MRI

Undergo biopsy

他の名前:
  • Bx
  • 生検

Undergo CT or PET/CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ断層撮影
  • CTスキャン
  • コンピュータ化されたアキシャルトモグラフィー
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン

Undergo PET/CT

他の名前:
  • 医用画像、陽電子放出断層撮影
  • ペット
  • PETスキャン
  • PT
  • 陽電子放出断層撮影スキャン

Given IV

他の名前:
  • テセントリク
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA

Undergo urine and blood sample collection

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集

Undergo high-dose EBRT

他の名前:
  • EBRT
  • 根治的放射線療法
  • 外部ビーム放射
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 放射線、外部ビーム
  • 遠隔放射線療法
  • 遠隔治療
  • 遠隔治療放射線
  • 外照射療法(従来)

Undergo apheresis

他の名前:
  • アフェレシス
  • アフェレーズ
  • 血液成分除去
  • コレクション、アフェレーシス/白血球アフェレーシス
  • ヘマフェレーシス

Given IM

他の名前:
  • プレベナー 13
  • PCV13
  • PCV13ワクチン

Given IT

Undergo EGD

他の名前:
  • EGD
  • 上部内視鏡検査
実験的:Pilot study (pheresis, EBRT, dendritic cells, Prevnar)

Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. (CLOSED WITH AMENDMENT 3)

Undergo high-dose EBRT

他の名前:
  • EBRT
  • 根治的放射線療法
  • 外部ビーム放射
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 放射線、外部ビーム
  • 遠隔放射線療法
  • 遠隔治療
  • 遠隔治療放射線
  • 外照射療法(従来)

Undergo apheresis

他の名前:
  • アフェレシス
  • アフェレーズ
  • 血液成分除去
  • コレクション、アフェレーシス/白血球アフェレーシス
  • ヘマフェレーシス

Given IM

他の名前:
  • プレベナー 13
  • PCV13
  • PCV13ワクチン

Given IT

実験的:Phase II Group 3 (EBRT, dendritic cells, Prevnar, atezo, tir)

Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

Undergo MRI

他の名前:
  • MRI
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 構造MRI

Undergo biopsy

他の名前:
  • Bx
  • 生検

Undergo CT or PET/CT

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ断層撮影
  • CTスキャン
  • コンピュータ化されたアキシャルトモグラフィー
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン

Undergo PET/CT

他の名前:
  • 医用画像、陽電子放出断層撮影
  • ペット
  • PETスキャン
  • PT
  • 陽電子放出断層撮影スキャン

Given IV

他の名前:
  • テセントリク
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA

Given IV

他の名前:
  • インフィンジ
  • MEDI-4736
  • MEDI4736
  • メディ 4736

Undergo urine and blood sample collection

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集

Undergo high-dose EBRT

他の名前:
  • EBRT
  • 根治的放射線療法
  • 外部ビーム放射
  • 外照射放射線治療
  • 外部ビーム RT
  • 外部放射線
  • 外照射療法
  • 放射線、外部ビーム
  • 遠隔放射線療法
  • 遠隔治療
  • 遠隔治療放射線
  • 外照射療法(従来)

Undergo apheresis

他の名前:
  • アフェレシス
  • アフェレーズ
  • 血液成分除去
  • コレクション、アフェレーシス/白血球アフェレーシス
  • ヘマフェレーシス

Given IM

他の名前:
  • プレベナー 13
  • PCV13
  • PCV13ワクチン

Given IT

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of significant toxicity (Pilot study)
時間枠:Up to completion of cycle 2 (each cycle is 28 days)

A significant toxicity is defined as a dose limiting toxicity that is possibly, probably, or definitely related to dendritic cell (DC) treatment. Toxicities will be assessed using the Cancer Therapy Evaluation Program active version of the Common Terminology Criteria for Adverse Events.

Up to completion of cycle 2 (each cycle is 28 days)
Progression-free survival rate at 2 years (Phase II)
時間枠:At 2 years

Defined as the time from registration to disease progression or death due to all causes.

At 2 years
PFS (Phase II Group 3)
時間枠:Up to 5 years

Defined as the time from registration to disease progression or death due to all causes.

Up to 5 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate
時間枠:Up to 1 year post treatment

The overall response rate will be estimated by the number of patients with an objective status of complete response (CR) or partial response (PR) divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate will be calculated.

Up to 1 year post treatment
Number of patients who received at least one dose of intratumoral DC injection
時間枠:Up to 1 year post treatment

The feasibility of the regimen will be estimated by the number of patients who received at least one dose of intratumoral DC injection divided by the total number of patients who received apheresis.

Up to 1 year post treatment
Clinical benefit rate
時間枠:Up to 1 year post treatment

The clinical benefit rate will be estimated by the number of patients with an objective status of stable disease or CR or PR at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculate

Up to 1 year post treatment
Time to response
時間枠:Up to 1 year post treatment

Time to response is defined for all evaluable patients who have achieved an objective response as the date of initiation of vaccination treatment to the date at which the patient's objective status is first noted to be either a CR or PR. Time to response will be summarized descriptively using Kaplan-Meier methodology.

Up to 1 year post treatment
Duration of response
時間枠:Up to 1 year post treatment

Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the earliest date progression is documented. Duration of response will be summarized descriptively using Kaplan-Meier methodology.

Up to 1 year post treatment
Overall survival
時間枠:Up to 5 years

Defined as the time from registration to death from any cause.

Up to 5 years
Progression-free survival
時間枠:Up to 5 years

Defined as the time from registration to disease progression or death due to all causes.

Up to 5 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in target lesion measurements
時間枠:Baseline up to 1 year post treatment

All enhancing lesions will be evaluated over time for each patient. The percent change from baseline in target lesion measurements will be assessed over time. Differences in values over time will be summarized descriptively and graphically.

Baseline up to 1 year post treatment
Change in immunologic correlates before and after vaccination treatment
時間枠:Baseline up to 1 year post treatment

Change in immunologic correlates before and after vaccination treatment will be evaluated and summarized both quantitatively and graphically. Each of the correlative endpoints will be summarized individually, but will also be evaluated in terms of their relationships to one another; i.e., will use Spearman rank correlation coefficient to assess the correlations between baseline levels as well as between changes before and after treatment in these immunologic markers. In addition, these immunologic markers will be correlated with cancer and treatment related outcomes (e.g. response, adverse events). Relationships will also be explored graphically using scatter plots.

Baseline up to 1 year post treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Lewis R. Roberts, MD, PhD、Mayo Clinic in Rochester
  • 主任研究者:Lionel Kankeu Fonkoua, MD、Mayo Clinic in Rochester

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年9月19日

一次修了 (推定)

2030年8月31日

研究の完了 (推定)

2030年8月31日

試験登録日

最初に提出

2019年5月6日

QC基準を満たした最初の提出物

2019年5月7日

最初の投稿 (実際)

2019年5月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する